10:50 AM EDT, 06/06/2024 (MT Newswires) -- Syndax Pharmaceuticals ( SNDX ) said Thursday it has advanced into the phase 1b segment of its phase 1/2 proof-of-concept trial of revumenib as a monotherapy for patients with relapsed or refractory metastatic microsatellite stable colorectal cancer.

The trial's Independent Data Monitoring Committee recommended advancing to the next phase following the favorable safety profile noted in the phase 1a portion of the trial, the company said.

The trial aims to evaluate the safety, tolerability, and anti-tumor effects of revumenib in patients with relapsed or refractory metastatic microsatellite stable colorectal cancer.

Shares of the company were down 1.1% in recent trading.

Price: 19.03, Change: -0.18, Percent Change: -0.94